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The archazolids are a family of natural products that display powerful growth inhibitory 
activity against a number of human cancer cell lines. This activity has been linked to inhibition 
of the vacuolar-type ATPase (V-ATPase) and more recently cyclooxygenase (COX) enzymes. 
Using the archazolid structure as a starting point, several simplified analogues have been 
prepared and assayed for their V-ATPase and COX inhibitory activity. These simplified 
analogues were prepared using a novel Suzuki coupling with yields over 80%. They were 
assayed to investigate both their V-ATPase and COX inhibitory activity. In our assays there was 
no COX inhibition, while there was measurable V-ATPase inhibition. The V-ATPase inhibition 
showed an important difference between the natural product triene (ZZE) and an isomer (ZEE 
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Chapter 1. Introduction 
1.1 Isolation and Structural Determination of the Archazolid Natural Products 
 Archazolids are a family of natural products comprised of six (A-F) chemically distinct 
yet structurally related members (Figure 1-1). The first of the archazolids were discovered in 
1993 when Sasse et al. were testing for biologically active metabolites from myxobacteria in a 
screening assay with L929 mouse fibroblasts. Sasse et al. found a strain of Archangium gephyra 
whose extracts showed high cytotoxic activity (Table 1-1). Ultimately this activity was 
determined to arise from two structurally related compounds deemed to be archazolid A and B 
(Figure 1-1).1 As the study of these natural products continued, the general structures of both 
archazolids A and B were determined by Höfle and Steinmetz in 2003 by the use of 1H and 13C 
NMR, COSY, NOE, and HMQC data. In confirmation of the spectral assignments, the analysis 
of a 13C-labeled sample of archazolid A was procured by feeding a sample of 13C-enriched 
acetate and methionine to Archangium gephyra.2 In 2006 the absolute and relative 
stereochemistry of both archazolid A and B were determined by Menche et al. through the use of 
high field NMR studies along with molecular modeling and derivatization. It was determined 
that the unique structure of archazolid A and B possesses a 24-membered lactone ring with a 
thiazole side chain, seven alkenes (2E, 5E, 9Z, 11Z, 13E, 18E, 20E), as well as a complex 
sequence of eight methyl- and hydroxyl- bearing stereocenters.3 This was followed by Menche et 
al. publishing the first total synthesis of archazolid A and Trauner et al. publishing the first total 
synthesis of archazolid B, both in 2007.4,5 A. gephyra is the source for archazolid A, B, and F, 
while another myxobacterial strain, Cystobacter violaceus, produces the glycosylated archazolids 
C, D, and E.6,7,8 Although archazolids are structurally complex, they are attractive synthetic 
targets due to their nanomolar inhibitory activity of vacuolar-type ATPases (V-ATPases) which 
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are important therapeutic targets (vide infra), and low availability from the natural sources 
(roughly 200 mg from 350 L fermentation for archazolid A). 
 
Figure 1-1. Archazolid family of natural products.  
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Table 1-1. IC50 values for the archazolid natural products against murine cell line L-929. 
 
1.2 Biological Importance of the Archazolids: V-ATPase Inhibition 
 Vacuolar-type ATPases, or V-ATPases, are ATP-dependent proton pumps that control 
pH by shuttling protons in various endomembrane systems. They are commonly found in 
intracellular organelles as well as the plasma membrane. The V-ATPase is comprised of two 
domains that are made up of a total of 21 to 22 subunits. The V1 and V0 domains are responsible 
for ATP-hydrolysis to ADP and transporting protons, respectively. The V1 domain resides in the 
cytoplasm and is made up of a total of 8 subunits, A-H (Figure 1-2). Within this domain, there 
are a total of 13 to 14 units with three A and B subunits, a single C, D, E, and F subunit, along 
with two G subunits and one to two H subunits. The V0 domain is bound to the membrane and is 
comprised of subunits a, d, e and six c subunits labelled as 2c, 2c’, 2c’’. These six c subunits 
form a rotor like domain that binds protons and transports them from the cytoplasm to the 




Figure 1-2. The V-ATPase. 
Due to their ability to control the pH, V-ATPases are hypothesized to create an acidic 
pericellular microenvironment that promotes the activity of invasive proteases, such as Cathepsin 
B.10 It has also been seen that a phenotype of invasive of cancer cells correlates to upregulated 
V-ATPase activity and expression.11 This upregulated activity along with acidified 
microenvironment allow for survival and growth of cancer cells. The V-ATPase is therefore a 
promising molecular target for inhibition as a cancer therepeutic.12  
 Currently there are two well-known and studied inhibitors of V-ATPase, concanamycin 
and bafilomycin (Figure 1-3). These are both members of the plecomacrolide family of natural 
products. Plecomacrolides are a subset of the polyketides, where “pleco” describes their 





Figure 1-3. Plecomacrolide natural products bafilomycin and cocanamycin. 
While both concanamycin and bafilomycin are potent V-ATPase inhibitors with IC50 
values in the nanomolar range, information from studies using these compounds on the signaling 
pathways affected by V-ATPase inhibition is limited.14 This is due in part to concanamycin and 
bafilomycin also interacting with phosphorylation ATPases (P-ATPases) at concentrations in the 
micromolar range. Both archazolid A and B have been shown to be highly potent inhibitors of 
the V-ATPase, however they do not inhibit P-ATPases like bafilomycin and concanamycin. This 
difference is attributed to differences in the mechanism of action between the two classes of 
inhibitors. The plecomacrolides bind between two c subunits within the V0 domain whereas the 





Figure 1-4. Binding sites of the archazolids (blue stars) and the plecomacrolides (red stars) on 
the V-ATPase c subunits. 
 
V-ATPases have been increasingly studied as of late due to their upregulation in 
cancerous cells. In 2017, Merk et al. published a study on the relationship between V-ATPases 
and tumor initiating cells (TIC).16 TICs as of late have shown increased resistance to 
chemotherapeutics that can account for tumor metastasis and reoccurrence. TICs limit most 
therapeutic success and cause relapses. TIC’s ability for self-renewal and invasiveness have been 
correlated with the epithelial-mesenchymal transition (EMT).16 EMT confers a mesenchymal 
stem-like phenotype to cells, which causes cancer cells to become highly malignant and invasive, 
giving them self-renewal capacity and elevated resistance to therapeutics. EMT causes a change 
in structural proteins that maintain the cytoskeleton and cell-cell adhesions, and potentially most 
importantly, the loss of E-cadherin.16 E-cadherin is responsible for cell-cell contact and, when 
removed from the cell, this allows mesenchymal cells to be freed and become mobile within the 
body. Merk et al. discovered that V-ATPase inhibition disturbs the loss of E-cadherin by 
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preventing its internalization and recycling. This then disrupts the process of EMT and makes the 
TICs less invasive, diminishing their ability for self-renewal as well as decreasing their 
resistance to therapeutics.16 
 Due to V-ATPases strong correlation with the robustness of cancer cells, especially the 
TICs, they make interesting inhibition targets for anti-cancer activity drugs. The archazolids 
represent a potential starting point for further investigation of V-ATPase inhibition and 
development of new cancer therapeutics. However, before a thorough investigation of this type 















Chapter 2. Previous Syntheses of the Archazolids 
2.1 Synthesis of Archazolid A  
 In 2007, the first synthesis of archazolid A was published by Menche and Hassfield. 
Their synthesis was based on the combination and assembly of three pieces, which are detailed in 
the retrosynthetic plan shown in Scheme 2-1.1 
 Scheme 2-1. Menche's retrosynthetic approach to archazolid A. 
 
The E-alkene at C13-C14 was planned to result from an aldol condensation between 2-2 
and 2-3, while the C18-C21 E,E-diene would result from a Heck coupling between iodide 2-2 
and alkene 2-4. In order to complete the macrocyclic ring, a Horner-Wadsworth-Emmons 
(HWE) olefination would be employed. This synthesis is flexible in that either the HWE or an 




Scheme 2-2. Synthesis of fragment 2-2. 
 
The synthesis of iodide 2-2 (Scheme 2-2) begins with the E-vinyliodide 2-6, which was 
prepared by a known procedure.2 The acid in 2-6 was reduced to an alcohol and then oxidized to 
an aldehyde producing 2-7 in 85% yield over the two steps.2 Aldehyde 2-7 was then used in an 
anti-aldol coupling through the use of Masumune’s chiral ephedrine-derived ethyl ketone 2-8. 
This was done in order to install the methyl and methoxy stereocenters at C16 and C17, 
respectively, found in the natural product.3 A 96% yield was obtained for this reaction with a 
diastereoselectivity of >20:1. The resulting product 2-9 was methylated using Ag2O/MeI and the 
ephedrine auxiliary was reductively removed using LiAlH4 to give alcohol 2-10. Fragment 2-2 
was then completed by oxidation of the hydroxyl using Dess-Martin periodinane (DMP), methyl 
Grignard (MeMgBr) addition, and then oxidation again by DMP to afford ketone 2-5 (Scheme 2-
2). 
As shown in Scheme 2-3, the synthesis of C3-C11 fragment 2-3 uses a boron-mediated 
Paterson aldol reaction of the lactate derived ethyl-ketone 2-11 and aldehyde 2-12.4 This aldol 
reaction resulted in the anti-aldol product 2-13 with high diastereoselectivity (>20:1) and yield 
(88%). The free hydroxyl was protected using TBS and aldehyde 2-14 was afforded in 85% yield 
10 
 
through a sequence of reduction and periodate cleavage. Aldehyde 2-14 was then subjected to a 
Still-Gennari modified HWE olefination with phosphonate 2-15.5 Through the use of both 
KHMDS as the base and 18-crown-6, the Z-enone 2-16 was obtained in an 88% yield. After 
conversion to the aldehyde through a reduction (DIBAl-H) and oxidation (MnO2), a Still-
Gennari HWE was performed again to achieve the Z-enone 2-17 in 80% yield. Reduction with 
DIBAl-H and oxidation with DMP then gave the completed fragment 2-3 in 90% yield. 
Scheme 2-3. Synthesis of fragment 2-3. 
 
In Scheme 2-4, the synthesis of fragment 2-4 is described. This synthesis starts with the 
conversion of alpha-hydroxyacid 2-18 to the thioamide 2-19 in 58% yield over four steps. This 
was done through an amide formation, hydroxyl protection with TBSCl and the use of the 
Lawesson reagent. This thioamide was then cyclized through the use of bromo-ester 2-20. 
11 
 
Deprotection of the TBS-group with TBAF gave 2-21 in 76% yield from 2-19. The free hydroxyl 
in 2-21 was then converted to a carbamate through the use of carbonyldiimidazole and trapping 
of the activated carbamate with methylamine to form 2-22 in 94% yield. After the reduction of 
ester 2-22 to aldehyde 2-23 through the use of DIBAl-H, the complete fragment 2-4 was 
prepared using Brown’s asymmetric crotylation protocol in a good yield of 65%.6 
Scheme 2-4. Synthesis of fragment 2-4. 
 
In order to complete the synthesis of archazolid A (Scheme 2-5), fragments 2-2 and 2-3 
were combined through a boron-mediated aldol reaction followed by a two-step elimination to 
give 2-24 (94%, 2 steps). Then, 2-24 was reacted with 2-4 in a Heck reaction by heating the 
mixtutre to 80 ℃ in the presence of the catalyst PdCl2(PPh3)2, along with TBSCl, TEA, and a 
solution of CH3CN/H2O to give 2-25 with 6:1 E/Z selectivity. Compound 2-26 was obtained 
12 
 
from 2-25 through the attachment of the phosphonate 2-5 by use of BOP, oxidative removal of 
the PMB protecting group, and Swern oxidation to the aldehyde. Macrocyclization of the 
resulting keto-phosphonate 2-26 was accomplished using NaH as base. After macrocyclization, 
the C15 ketone was stereoselectively reduced through the use of an oxazaborolidine-assisted 
borane ((S)-CBS) reduction in 73% yield and d.s. >20:1.7 Finally, deprotection with HF/pyridine 
in THF gave archazolid A (2-1) in 80% yields.8 Overall, the longest linear sequence of the 
scheme was 20 steps with a yield of 4%.   




2.2 Synthesis of Archazolid B 
 Due to the high bioactivity and fascinating structural features, Trauner, Roethle, and 
Chen pursued the synthesis of archazolid B (2-27). Key transformations of their synthesis 
include a Hoye relay ring-closing methathesis (RRCM), a Stille coupling at C10-C11, and a Kita 
esterification utilizing three fragments: 2-28, 2-29, and, like Menche, 2-4 (Scheme 2-6).9 Overall, 
their synthesis had a longest linear sequence of 19 steps and an overall yield of 0.8%.  
Scheme 2-6. Trauner’s retrosynthetic approach to archazolid B (2-27). 
 
The three fragments 2-28, 2-29, and 2-4 were designated by the group as the 
northwestern, northeastern, and southern fragments respectively based on their location within 
the molecule as commonly drawn. The northeastern fragment was synthesized by starting with 
known ynone 2-31 available from the (S)-Roche ester 2-30, as shown in Scheme 2-7.10 
Compound 2-31 was taken through a highly diastereoselective reduction with (S)-alpine borane 
to give a secondary hydroxyl, which was then protected as its triisopropylsilyl (TIPS) ether.  
Selective deprotection of the TBS-group gave primary alcohol 2-32 in 80% yield. Oxidation of 
the primary alcohol through the use of DMP and NaHCO3 led to an aldehyde, which was then 
14 
 
subjected to a Cory-Fuchs transformation using triphenylphosphine, potassium bicarbonate, and 
carbon tetrabromide in order to achieve dibromide 2-33 in 75% yield. Conversion of 2-33 to the 
(Z)-vinyl iodide 2-34 was accomplished using the method developed of Tanino and Miyashita, 
which involved methyllithium, copper(I) iodide and I2.
11 This was followed by the exchange of 
the secondary silyl protecting group (TIPS) for a secondary tert-butylcarbonate (Boc) protecting 
group (76% over two steps). They performed this exchange of protecting groups so that there 
was the presence of a coordinating carbonate, which encouraged high regioselectivity in the 
Trost Alder-ene reaction. Compound 2-34 was then subjected to a highly selective Trost Alder-
ene reaction with 3-butenol to afford the triene 2-35 in 88% yield, which contained the sensitive 
skipped diene found in the natural product that has been seen to be prone to isomerization.12 
Compound 2-35 was then oxidized in a two-step process to afford the “northeastern” carboxylic 
acid 2-29 in nearly quantitative yield for the two steps (Scheme 2-7).  




 As shown in Scheme 2-8, the synthesis of the northwestern fragment (2-28) began with 
iodoenoate 2-36, which was obtained in three steps from a propargyl alcohol.13 Reduction by 
DIBAl-H followed by an oxidation to the aldehyde with DMP was followed by an efficient 
Evans syn-aldol addition with the boron enolate of benzyl oxazolidinone 2-37 to afford 2-38 in 
73% for the three steps. This was then converted into the corresponding Weinreb amide, which 
was followed by a TBS protection of the secondary free hydroxyl. The Weinreb amide then 
underwent a phosphonate Claisen reaction to give a beta-keto phosponate 2-39, with a yield of 
68%. This phosphonate was then subjected to a HWE reaction with the enal 2-4 to afford 2-41 in 
79% yield. A highly diastereoselective reduction with NaBH4 followed by etherification and an 
iodine-tin exchange gave the completed northwestern fragment 2-28 in 70% yield over three 
steps. Trauner et al. did not report confirmation of the stereochemistry from their NaBH4 
reduction at this stage, however, they were able to match their final archazolid B NMR to the 
isolated NMR. 




 The synthesis of the southern thiazole fragment 2-4 is shown in Scheme 2-9 and was built 
upon the known hydroxyalkyl thiazolecarboxylate 2-43, available in a six step synthesis from 
leucine 2-42.14 Compound 2-43 was then subjected to carbamoylation with carbonyldiimidazole 
(CDI) and methylamine followed by a chemoselective reduction of the ester and Brown 
crotylation of the resulting aldehyde.15 In this way fragment 2-4 was obtained in 9 steps and 30% 
yield from leucine (Scheme 2-9). 
Scheme 2-9. Trauner’s synthesis of fragment 2-4. 
 
Once the fragments had been synthesized, the southern fragment 2-4 and northeastern 
fragment 2-29 were combined using a ruthenium catalyzed Kita esterification to form 2-44 
(Scheme 2-10).16 The authors note that this type of esterification was required because “all base-
mediated methods led to the migration of the C2-C3-double bond.” Due to this isomerization in 
basic conditions, esterifications such as the Yamaguchi esterification17 could not be utilized due 
to their basic additives (e.g. triethylamine/DMAP). 




 Once esterified, 2-44 was subjected to a thermal deprotection of the Boc group with silica 
to afford the corresponding free hydroxyl (Scheme 2-11). It could be that the Boc group was 
removed prior to the coupling because of the instability of the triene, thus once the coupling 
occurred the triene would decompose during deprotection. This was followed a modified 
Liebskind coupling with vinyl stannane 2-28 to give the relay ring closing metathesis precursor 
2-45 in 21% yield.18 
Scheme 2-11. Synthesis of fragment 2-45. 
 
The RRCM used a second generation Grubb’s catalyst and afforded a 27% yield of the 
macrocycle (Scheme 2-12).18  Deprotection of the TBS group using a solution of formic 
acid/THF/H2O in a 3:6:1 ratio then completed their synthesis of archazolid B (2-27). 




2.3 Modular Synthesis of Archazolid A and B  
 In 2009, Menche and Hassfeld published a modular total synthesis of archazolid A and B, 
with the key difference being the use of different phosphonates, 2-5 or 2-46 to access archazolid 
A and B, respectively (Scheme 2-13).19 Overall, they improved their previous synthesis of 
archazolid A by using the same three of four fragments (2-2 through 2-4), but they optimized 
their reaction procedures and investigated alternative fragment coupling sequences. This modular 
approach allowed the Menche group the freedom to change the order of addition of fragments. 
Scheme 2-13. Menche’s modular retrosynthesis of archazolid A (2-1) and B (2-27). 
 
From the previously reported synthesis of 2-4, there were reports that when installing the 
thiazole ring, epimerization of the free hydroxyl stereocenter occurred. Menche and Hassfeld 
corrected this by oxidizing that hydroxyl group to the ketone 2-47, which was followed by a 
stereoselective reduction with (R)-CBS to give the enantiopure 2-21 (Scheme 2-14). This was the 
only change made to the synthesis of fragment 2-4.  
19 
 
Scheme 2-14. Revised strategy for synthesis of 2-21. 
 
When attempting to optimize the synthesis of fragment 2-2, the removal of the Abiki-
Masamune auxiliary was investigated due to the multitude of steps outlined in Scheme 2-2. It 
was found that if the ester carbonyl was activated by coordination to the free hydroxyl using a 
Lewis acid, promoted the nucleophilic attack of the N-(methoxylmethyl)methyl amine 2-48 to 
give Weinreb amide 2-49 (Scheme 2-15). The highest yields were obtained using i-PrMgCl as 
the coordinating Lewis acid. In this way 2-49 was obtained in 72% and could be transformed to 
the methyl ketone 2-2 in two steps with a 74% yield. 
Scheme 2-15. Revised strategy for the synthesis of fragment 2-2. 
 
Previously unreported, macrocyclization of 2-26 to 2-1 (archazolid A) with a base caused 
the anti-propionates (C7/C8 and C16/C17) to undergo elimination rather than cyclization to achieve 
archazolid A. The elimination was overcome by the use of molecular sieves. It was theorized that 




Figure 2-1. Positions C7-C8 and C16-C17 were prone to elimination under mild reaction 
conditions. 
 
In order to demonstrate the modularity of their synthetic approach and avoid elimination 
during HWE cyclization, the synthesis of archazolid B (2-27) was investigated using a different 
order of the fragment coupling process (Scheme 2-16). Phosphonate 2-50 resulted from the 
addition of phosphonate 2-46 with BOP to fragment 2-4. Aldehyde 2-51 was afforded from 
deprotecting the primary PMB group on 2-24 followed by a Swern oxidation. Compounds 2-51 
and 2-50 were stitched together through the use of an intermolecular HWE to give 2-52. After 
the olefination, an intramolecular Heck macrocyclization was performed, followed by a 
stereoselective CBS reduction of the ketone to the free hydroxyl. Finally, HF/pyridine was used 
in the TBS deprotection using to give 2-27 (Scheme 2-16). 
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2.4 Highly Stereo- and regioselective approach to the C9-C12 fragment of the archazolids 
 One of the important and most interesting structural features of the archazolid natural 
products is the C9-C12 (Z,Z)-1,1,3,4-tetrasubstituted 1,3-diene which is part of a conjugated 
triene.20 Menche’s group ultimately utilized a 3-step aldol condensation after attempted Horner-
Wadsworth-Emmons reactions failed, which then required a late-stage enantioselective CBS-
reduction to install the C15 hydroxyl.
21 Trauner’s Stille coupling at C10-C11 to complete the 
triene was successful but low-yielding (21%). In 2007, Negishi and Huang published an elegant 
approach to this synthetically challenging subunit (Scheme 2-17). This synthesis was 
accomplished by hydroboration of a 1-halo-1-alkyne. Following this was a migratory insertion of 
2-54 after the addition of dimethyl zinc and a zinc promoted transmetalative iodinolysis to 
ultimately give compound 2-57. Compounds 2-58 and 2-57 were then cross-coupled through 
palladium catalysis to give the conjugated triene 2-59 in good yields (83% for 2-59a; 81% for 2-
59b) as shown in Scheme 2-17. Interestingly, Negishi et al. use a similar disconnection approach 
as Trauner et al. (i.e. at C10-C11), but have a four-fold improvement of yields. Two protocols 
described, using either Zn-II or Zn-III, have provided potential intermediates for the synthesis of 
archazolids as isomerically ≥98% pure, however Negishi’s group has not yet published any 
further synthetic studies on the archazolids. 
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Scheme 2-17. Negishi and Huang’s synthesis of the C9-C12 triene fragment of the archazolids. 
 
2.5 Previous Syntheses by the O’Neil Group 
In 2011, archazolid F was discovered and isolated from the same bacterium, Archangium 
gephyra.22 Archazolid F introduced a slightly new structure, but a similar activity to both 
archazolid A and archazolid B.15 Instead of the alkene at C2 it was now shifted to C3. Due to the 
similar potency of archazolid F to archazolid B despite this structural change, it was 
hypothesized by our group that an analog of ArcB with the removal of the alkene at C2 would 
retain its biological activity.23 This new compound, dihydroarchazolid B (DHArcB), thus became 




Figure 2-2. Comparison between archazolid B and archazolid F as a basis for the simplified 
archazolid, dihydroarchazolid B. 
From the decision to synthesize dihydroarchazolid B, a retrosynthesis was proposed by 
the O’Neil group (Scheme 2-18). DHArcB was split into three fragments that we refer to as the 
western fragment (2-61), the eastern fragment (2-60), and the side-chain 2-62.  




 The synthesis of 2-60, the eastern fragment, began with the TBS protection of 5-hexyn-1-
ol (2-63) to 2-64 (Scheme 2-19). Compound 2-64 was then added to aldehyde 2-65 using 
trimethylaluminium and zirconocene dichloride, delivering 2-66 in 85% yield and with a 6:1 
diastereomeric ratio.24 The free hydroxyl was protected as its TBS-ether and the PMB protecting 
group was removed affording a primary alcohol that was oxidized using Swern conditions to 
form 2-67. Aldehyde 2-67 was then reacted using a Still-Gennari modified Horner-Wadsworth-
Emmons reaction5 in order to generate the z-ester 2-69. The primary TBS protected hydroxyl 
was oxidized directly to the carboxylic acid by treatment with the Jones reagent and the ester was 
reduced to the alcohol and oxidized to the aldehyde to form 2-71. This aldehyde was then taken 
through the tandem allylzirconation/Peterson elimination sequence of Huang and Pi to generate 
the Z,Z-terminal triene 2-60 with 8:1 diastereoselectivity.25 
Scheme 2-19. Completion of the eastern fragment, EZZE-triene 2-60. 
 
 For 2-61, the western fragment, the synthesis begins with the well-established synthesis 
of the Weinreb amide 2-75 (Scheme 2-20).26 This was then converted to the ketophosphonate 2-
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77, which allowed for a Horner-Emmons coupling27 with the (R)-Roche ester derived aldehyde 
2-78 using Ba(OH)2•8H2O for the highest trans-selectivity (>10:1).
28 The ketone was then 
converted to the methylether present in 2-80 by first a diastereoselective reduction with NaBH4 
followed by methylation of the resulting hydroxyl with LiHMDS and methyl triflate (MeOTf). 
The primary TBS group in compound 2-80 was then removed using HF/pyridine and the 
resulting primary alcohol was oxidized to the aldehyde using DMP to give 2-61.29 
Scheme 2-20. Completion of the western fragment 2-61. 
 
The side chain was synthesized from known ketothiazole 2-62 (Scheme 2-21).30 The 
ketone in 2-62 was enantioselectively reduced using the CBS reagent and the resulting free 
hydroxyl31 was protected as its TES-ether to give 2-81 in 74% for the two steps. Compound 2-81 
was then treated with tert-butylithium for a lithium-halogen exchange with the bromide and the 
resulting organolithium was added to the western aldehyde fragment 2-61 to produce 2-82 as a 
mixture of diastereomers.32 The free hydroxyl was then oxidized to the ketone using DMP and 
the TES group was deprotected using a mixture of HF/pyridine at 4 ℃. Then in order to 
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complete the western half of the archazolid, methyl amine and CDI were employed to install the 
carbamate found in compound 2-83. 
Scheme 2-21. Thiazole fragment coupling to the western fragment 2-61. 
 
Once 2-83 had been produced, the ketone was stereoselectively reduced using L-
Selectride and esterified with 2-60 using Yamaguchi’s conditions (2,4,5-TCBC, TEA, and 
DMAP) to generate 2-84 as shown in Scheme 2-22. This set up an attempted macrocyclization 
by ring-closing metathesis. 
Scheme 2-22. Esterification of the eastern and western fragments 2-60 and 2-83. 
 
Using a ruthenium based catalyst, attempts were made to complete the synthesis of the 
protected DHArcB by RCM (Scheme 2-23). Unfortunately, it was discovered under a wide range 
of conditions that the catalyst was back biting instead of forming the macrocycle. Specifically, 
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after engagement of the western alkene, it was cyclizing to create a cyclopentene with loss of 
ethylene.33 
Scheme 2-23. Attempted coupling of the triene through RCM. 
 
 
 Due to this competing back-biting during the attempted ring closing metathesis 
macrocyclization, a new cross metathesis was investigated. This was attractive because of the 
higher likely trans-selectivity that would be expected from the cross metathesis. However, 
knowing that the back-biting could occur, the fragments involved in the cross metathesis could 
not involve and the completed western fragment. Instead, a simpler cis-homodimer was 
investigated as a coupling partner with the eastern fragment 2-60.   
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Scheme 2-24. Synthesis of the cis-homodimer 2-85. 
 
 The cis-homodimer 2-85 was synthesized by starting with two equivalents of 2-86 and 
tethering them with diphenyldichlorosilane giving 2-87 (Scheme 2-24). Silyl-tethered RCM of 2-
87 lead to a cis-siloxane 2-88, which was desilylated with TBAF to give the cis-homodimer 2-
85. Overall, the cross metathesis with the cis-homodimer was successful in creating the desired 
product (Scheme 2-25). It was discovered that the optimal conditions were three equivalents of 
2-85 using the Hoveyda-Grubbs ruthenium catalyst over 36 hours. However, this reaction could 
only produce a maximum of 40% yield, which lead to investigations into other coupling 
options.34 
Scheme 2-25. Coupling of the cis-homodimer 2-85 with the eastern fragment 2-60. 
 
 When considering an alternative non-metathesis based archazolid synthesis, we still 
wished to make use of the previously developed chemistry for the separate fragments. 
Ultimately, this led to the employment of a Stille coupling. Both the western and eastern 
30 
 
fragment syntheses were adjusted to create a halide eastern fragment and an organostannane 
western fragment. 
Scheme 2-26.  Synthesis of the revised organostannane western fragment 2-96. 
 
For the western fragment, the synthesis started with the known Weinreb amide 2-93 
(Scheme 2-26).35 This was converted to phosphonate 2-94. Through a Horner-Wadsworth-
Emmons olefination with aldehyde 2-78, ketone 2-95 was obtained. The ketone was 
stereoselectively reduced and methylated as previously described giving 2-96 in 63% yield for 
the two steps. Synthesis of the eastern fragment halide began again from 2-69 (ref. Scheme 2-
18), however the primary TBS protected hydroxyl was not oxidized to the carboxylic acid at this 
time. Instead, the Still-Gennari installed ester was reduced and oxidized to the aldehyde 2-90 and 
an iodo-Wittig with in situ-prepared phosphorane 2-91 was employed to create the vinyl iodide 
2-92 (Scheme 2-27).   
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Scheme 2-27. Synthesis of the revised eastern fragment 2-92. 
 
 With both the western and eastern fragments in hand, a Stille coupling was attempted. 
However, this reaction gave mostly unreacted vinyl iodide 2-92, suggesting difficulties in the 
oxidative addition step of the catalytic cycle. It was hypothesized that switching the iodide and 
stannane positions could provide less sterically hindered conditions for the oxidative addition 
step. To that end, stannane 2-95 was iododestannylated to give iodide 2-96, and iodide 2-92 was 
converted into stannane 2-97 by lithium-halogen exchange and trapping with Bu3SnCl.
36 
Compounds 2-97 and 2-96 underwent an efficient Stille coupling using Fürstner’s conditions, 
providing 2-98 in 82% yield37 (Scheme 2-28). 







 One main goal of this project was to understand the structure activity relationship, SAR, 
of the archazolids for V-ATPase inhibition. The O’Neil group had previously tested three 
archazolid fragments in an Arabidopsis-based V-ATPase assay using the compounds that they 
had synthesized (2-99, 2-100, and 2-10138), which are in Figure 2-3.  
 
Figure 2-3. The compounds that were used in an Arabidopsis-based V-ATPase assay. 
 None of these compound inhibited Arabidopsis growth which is an indicator for V-
ATPase inhibition, leading the group to believe that macrocyclization is important for inhibition. 
Additionally, the C7 and C15 hydroxyls linked by the Z,Z,E-triene appeared to be important for 
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V-ATPase inhibition, as evidenced by the lower V-ATPase inhibitory activity of archazolids C 
and E where these hydroxyls are glycosylated (Figure 2-4). While compounds 2-99 through 2-
101 did not contain an intact C7-C15 subunit, our Stille coupling product 2-102 (after 
deprotection) contained this important region of the archazolid structure. We hypothesized, 
therefore, that compound 2-102 might display V-ATPase inhibitory activity. 
 
Figure 2-4. Demonstration of pharmacophore effects in 2-102. 
 To test this, compound 2-102 was subjected to our Arabidopsis-based V-ATPase assay 
and shown to have an IC50 = 25 μM (Figure 2-4). This important result provides further evidence 
that the C7 and C15 hydroxyls connected by the triene are a pharmacophore for V-ATPase 
inhibition. The IC50 of 2-102 was roughly 100 x higher than the well-established V-ATPase 
inhibitor cocanamycin A (IC50 = 0.25 μM), however. Nonetheless, the modest activity archazolid 
of 2-102 is still significant and this compound can serve as a starting point to further understand 




Figure 2-5. Arabidopsis-based V-ATPase inhibition of compound 2-102 and cocanamycin A. 
 In 2014, Reker et al. published a theoretical investigation into the biological activity of 
natural product derived fragments (NDPFs).39 This query led to the development of an algorithm 
that allowed them to computationally evaluate fragments of natural products that could be 
potentially potent drugs on well known drug targets. They used archazolid A as a model for this 
algorithm and published an archazolid A based fragment (2-103) that they believe would possess 
a low IC50 against the cyclooxygenase-2 (COX-2) enzyme (Figure 2-6). 
 
Figure 2-6. Reker et Al. predicted potent COX-2 inhibitor fragment 1. 
 The authors went on to argue that archazolid A has a similar structure to the native 
substrate for COX-2, arachidonic acid (Figure 2-7). However, when assayed, archazolid A only 
had a 24 ± 6% inhibition of COX-2 at 10 μM.39 Reker et al. justified this result with the fact that 
the inhibition site of COX-2 has a very narrow entry point, which could be blocking the large 
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macrocyclic structure of archazolid A, whereas arachidonic acid (and fragment 2-103) can get 
through due to its flexible and linear nature.39 Due to the similarity of the predicted COX 
inhibitor 2-103 and our synthesized compound 2-102, a COX-2 inhibition assay was performed. 
Somewhat surprisingly, compound 2-102 did not show any COX-2 inhibition (<5% at 200 μM), 
which could potentially be for two reasons: (1) either it is still too large to get to the buried site 
of inhibition, or (2) the carboxylic acid is a pharmacophore for COX inhibition.  
 
Figure 2-7. Structural overlay of arachidonic acid and archazolid A.39 
 COX-2 inhibition is important in anti-cancer activity because it is highly upregulated in 
cancer cells.40 It is also responsible for the inflammation response as well as proliferation of 
those cancer cells. Due to its importance in anti-cancer activity, and in order to better understand 
the lack of COX-inhibition for compound 2-102, we set out to synthesize the hypothetical COX-





Chapter 3: Synthetic Plan and Work towards Proposed COX-2 Inhibitor Fragment 1 (2-
103).  
3.1 Suzuki Coupling  
Even though the yields of the Stille coupling of 2-96 and 2-97 were high (82%, Scheme 
2-26), this type of cross-coupling is not ideal due to the toxicity associated with organotin 
compounds. As an alternative, Suzuki couplings are preferred. Both Stille and Suzuki couplings 
use a palladium catalyst, however the organostannane of the Stille is replaced with an 
organoborane for the Suzuki. Overall, the Suzuki coupling is a four-step process: oxidative 
addition, base removal of the halide, transmetalation, and reductive elimination as shown in 
Figure 3-1.  
 
Figure 3-1. General Suzuki coupling mechanism. 
Suzuki couplings were first discovered in 1979 and since then have become among the 
most widely applied palladium-catalyzed cross-coupling reactions.1,2 These C-C bond forming 
reactions have variable conditions (e.g. choice of palladium catalyst, base, solvent, temperature) 
that can be optimized for specific substrates. Attributes such as these allow for them to be scaled 
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for industrial applications as well as tailored to complex and unstable reactants. The number and 
type of applications has expanded exponentially since its discovery, culminating in a Nobel Prize 
in 2010. As shown in Figure 3-2, since 1995 reports of Suzuki couplings have been increasing 
almost exponentially. Directly comparing the Stille coupling to the Suzuki coupling, both have 
had an increase in the number of publications since the 1990s, however the Suzuki coupling has 
been increasing at a much higher rate, potentially due to its commercial availability of 
precursors, high stabilities or organoborane reagents towards air and moisture, and potentially 
the most important, its use of nontoxic boronic acids.  
 
 
Figure 3-2. Documents containing reports of Suzuki couplings versus the year.3 
 
Another comparison is presented in Figure 3-3, which describes the number of medicinal 
chemistry applications of different palladium-catalyzed reactions published over the last few 
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decades. As can be seen, Suzuki couplings have emerged as the most widely used palladium-
catalyzed process and among the most widely used of any reactions in this industry.4 
 
Figure 3-3. Two figures showing the asymptotic increase of Suzuki coupling reactions published 
as the reaction was discovered and utilized.5,6 
Our investigations into a potential Suzuki coupling-based synthesis of the archazolid 
triene began with attempting to establish proof of principle that this type of coupling would 
work. The reaction could then be optimized in order to generate sufficient material for further 
studies. As outlined in the table below, when optimizing Suzuki couplings there typically are six 
parameters that can be varied; 1) nature of the boronate, 2) halide, 3) palladium source, 4) base, 
5) solvent, 6) temperature of the reaction. 
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Table 3-1. The variable conditions of natural product synthesis utilizing Suzuki couplings, as 
detailed in by Koshvandi et al.7 
 
The first condition that is often adjusted is the boronic ester. A recent review from 
Koshvandi, covering just natural product syntheses featuring Suzuki couplings that have been 
published from 2012 until 2017 (and therefore not comprehensive), described a total of seven 
different boron groups that had been utilized. Examples of Suzuki couplings utilizing a pinacol 
borane and a boroxine are shown below in order to illustrate the wide variety of boron groups 
that can be used in a Suzuki coupling.7 A more complete list is given in Table 3-1.  
Catalyst Boronate Halide Base Solvents Temperature Range (°C)





DMF, tolune, ethanol, 









dioxane, water, DMF 80-100
Pd(PhCN)2Cl2 acid Cl CsF/TBAB toluene, water 60
Pd(PPh3)2Cl2 acid, pin Cl, I, Br
K3PO4, Na2CO3, 
NaOtBu, TEA






I, Br, Cl, OTf, 
Phos




dioxane, water, DMF, 
THF, methanol, DME, 






I, Br Na2CO3, Cs2CO3
DME, ethanol, THF, 
water
rt-100
Pd/C acid Br Na2CO3 methanol reflux
Pd2(dba)3 pin, acid I, Br, OTf
K3PO4, Cs2CO3, KF, 
Na2CO3
DMF, ethanol, water, 
toluene, THF, methanol 
rt-110
Pd2(PCy3)2 acid I Na2CO3 toluene, methanol 65
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Scheme 3-1. Two examples illustrating different boron groups used for Suzuki coupling. 
 
While these are two interesting examples, there are many other boron substituents that 
can be used. From a review published on the study of selecting boron reagents for Suzuki 
couplings, Lloyd-Jones et al. investigated the most common boron reagents. Within this review, 
they mapped out the uses, reactivity, and many other important attributes about specific boron 
species (Table 3-2)8. 
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Table 3-2. An example of the wide variety of boron groups as well as benefits and attributes8. 
 
Many different palladium sources can also be used ranging from Pd(dppf)Cl2 to Pd/C, 
with Pd(PPh3)4 seeming to be the most common. The different palladium sources change not 
only the reactivity of the palladium, for instance starting with palladium (0) or palladium (II), but 
the differing ligands on palladium can also have effects on the reaction as a whole. Shown below 
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are representative examples demonstrating the different types of palladium catalysts that can be 
chosen for Suzuki couplings (Scheme 3-2). 
Scheme 3-2. Three examples of different palladium sources used in Suzuki couplings. 
 
One of the most important parameters to consider, which is often dependent on the 
stability of the reactants, is the choice of base for the reaction. The role of the base in Suzuki 
couplings is to not only activate the palladium source (e.g. to palladium (0) if starting with 
Pd(II)), but also to activate the boronate for the transmetalation step. The review from Koshvandi 
presented 15 different bases used in successful Suzuki couplings, but again this was limited to 
five years and therefore represents only a portion of bases that have been used in Suzuki 
couplings. The bases not only vary in pKa, but also their size and counter ions, where again the 
choice of base is often influenced by substrate stability. Examples given in Scheme 3-3 show 
different bases ranging from NaOH to Ag2O and K3PO4. From the other examples of Suzuki 
couplings, it can be noted that carbonates (e.g. Na2CO3), hydroxides (e.g. NaOH), and other 
bases can be used (Scheme 3-3).  
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Scheme 3-3. Three examples of different bases used in Suzuki couplings. 
 
Other conditions that are often adjusted are the temperature of the reaction, the solvent, as 
well as any additives (AsPh3, P(t-Butyl)3, S-Phos) that might improve the reaction. Temperature 
can be increased to drive reaction progress. One method for accelerating Suzuki coupling by heat 
is to use microwave conditions. Microwave conditions can allow shorter reaction times due to 
more even heating within the reaction. For example, McCluskey et al. reported that the Suzuki 
coupling shown in Scheme 3-4 to create a biaryl framework gave only 13% yield after 5 days 
when performed under standard heating (refluxing THF) 9. However, when this reaction was 





Scheme 3-4. An example of microwave assisted Suzuki coupling improving yields as well as 
shortening the time of reaction.  
 
The choice of solvent allows for the most freedom in the Suzuki couplings with the 
qualifiers being that the reactants are soluble in the solvent as well as they will not interact with 
the catalyst or the base as a whole. However, as the push towards greener chemistry has gained 
more traction in research, there have been many recent publications with water being a part of 
the reaction mixture. This can be challenging, especially for natural product synthesis as many of 
these are small organic molecules that are not soluble in water. However, by adjusting the 
reaction conditions, Suzuki coupling of hydrophobic small molecules in water can still occur. 
One example is by Karimi et al. who used SiO2 to anchor hydrophilic triethylene glycol 
imidazolium to encapsulate the palladium catalyst and the substrates within the ionic liquid 







Scheme 3-5. An example of greener Suzuki couplings occurring within water. 
 
 
Substrate structure can also have a profound influence on the success of Suzuki 
couplings. The majority of the Suzuki reactions that have been reported occur between two sp2 
hybridized carbons, as Suzuki et al. first showed when they published their research in 1979.11 
However, recent publications have shown that Suzuki couplings can also be used between sp3 
and sp2 hybridized carbons (Scheme 3-6).12 This expanded scope makes this reaction seemingly 
limitless, and this reaction will no doubt continue to be a powerful tool in the organic chemist’s 
toolbox. 
Scheme 3-6. Examples of sp3-sp2 hybridized carbon Suzuki reactions. 
 
In order to narrow the possible Suzuki coupling conditions to be tested for our 
application, we opted to first investigate conditions that were used to couple fragments most 
similar to our own. In this way, a Suzuki reaction reported by Menche et al. that was used to 
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synthesize the complex polyene polyketide etnangien was identified.13 Due to the sensitive 
nature of the target polyene product, this group opted for the use of Ba(OH)2 as base. In this way, 
compounds 3-1 and 3-2 were coupled to give the product 3-3 in 83% yield. We anticipated that 
the archazolid conjugated triene Suzuki target would be similarly sensitive, and decided that 
these conditions would be the starting point for our own investigations.  
Scheme 3-7. Suzuki coupling within the synthesis of the complex polyene polyketide etnangien 
by Menche et al.13 
 
3.2 Synthetic Route Changes 
My work began on the eastern fragment synthesis of dihydroachazolid B, adjusting the 
synthesis slightly to install a vinyl boronate rather than a vinyl stannane so that a Suzuki 
coupling could be employed rather than a Stille coupling. Overall, the general scheme stayed the 
same except for the last step, where instead of doing a transmetallation to a vinyl stannane from a 
vinyl iodide, we would employ a lithium halogen exchange and trapping with isopropoxy 
boronate and pinacol, in order to make the pinacol boronic ester as shown in Scheme 3-8. 
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Scheme 3-8. The updated eastern fragment 3-4 for Suzuki Coupling. 
 
Working our way through the eastern fragment synthesis, it was realized that the overall 
progression  was slowed down by the synthesis of the Still-Gennari phosphonate reagent 2-68.14 
This compound was obtained by methylation of the commercial trifluoroethyl phosphonate 3-5 
with KOtBu and methyl iodide. However, this reaction often proceeded with incomplete 
conversion giving a mixture of phosphonates 3-5 and 2-68 that were difficult to separate. 
Moreover, any amount of non-methylated 3-5 in the subsequent Still-Gennari produced the 
disubstituted alkene 3-6 that could not be separated from the desired trisubstituted alkene 2-69 by 
chromatography on silica.  





Because of the difficulty of this process, a new eastern fragment synthesis was devised 
where instead of producing a cis-alkene using an intermolecular Still-Gennari, it would be 
installed by using an intramolecular Horner-Wadsworth-Emmons reaction. This new synthesis 
differed from the original synthesis after the zirconocene step at the free secondary hydroxyl 2-
66 (Scheme 3-10). The free hydroxyl was esterified with DCC and phosphonate 3-13 
(synthesized in three steps from dibromo 3-9 as shown in Scheme 3-10) to create ester 3-7. This 
ester was then taken through a PMB deprotection as well as oxidation to give aldehyde 3-8.  





 It was at this point that we could now employ the intramolecular Horner-
Wadsworth-Emmons to create the cis-alkene in the form of lactone 3-14.15 A number of bases 
were screened as outlined in Table 3-3. A mixture of products was observed when the HWE 
olefination was attempted. Through careful analysis of the two distinct products, it was 
determined that while our desired lactone was being created, the reaction was also producing the 
elimination product 3-15, presumably through the E2 mechanism (Scheme 3-11). 
Scheme 3-11. Formation of diene 3-15 through the E2 mechanism. 
 
 Multiple conditions were tested in order to receive the highest selectivity towards the 
desired lactone and it was found that through activation with barium hydroxide, a maximum of 








 Table 3-3. Optimization of intramolecular HWE reaction of 3-8 to produce lactone 3-14. 
 
Once the lactone was obtained, it was reduced to the lactol 3-16 with DIBAl-H, which is 
in equilibrium with the aldehyde 3-17. An iodo-Wittig was attempted using 
ethyltriphenylphosphonium iodide under the same conditions that were used for our previous 
Stille-based synthesis, but unfortunately only the starting lactol was ever recovered. It was 
hypothesized that the lactol was much more stable than the aldehyde 3-15 that was needed for 
the iodo-Wittig (Scheme 3-12). Thus, we attempted to warm the reaction slowly to room 
temperature in order to promote equilibration and create more of the aldehyde. However, this 
resulted in decomposition of the phosphonium-ylide, evidenced by loss of its characteristic 
bright red color upon warming. 
 
aDetermined by NMR. bLithium sources was LiCl. 
Base pKa Metal Chelator 3-14 : 3-15a 
TEA 9 Lithiumb 2:1 
K2CO3 10.25 Potassium 1:1 
DIPEA 10.75 Lithiumb 5:1 
DBU 12 Lithiumb 1:20< 
Ba(OH)2 15.7 Barium 5:1 
KHMDS 26 Potassium 1:20< 
NaH 35 Sodium 5:1 
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Scheme 3-12. Proposed pathway to synthesize vinyl iodide 3-18 from lactone 3-14. 
 
3.3 Boron-Wittig Chemistry 
Due to our inability to convert lactol 3-16 to vinyl iodide 3-18, a new method of 
installing a vinyl boronate was investigated. We envisioned an alternative Wittig approach but 
instead of using a phosphonium iodide, it would use an alkyl diboronate to directly convert lactol 
3-16 to vinyl boronate 3-19 as shown in Scheme 3-13. 
Scheme 3-13. Proposed pathway from lactol 3-16 to vinyl boronate 3-19 through a boron-wittig 
reaction. 
 
In 2010 Endo et al. published a new synthesis of tetrasubstituted alkenylboronates.16 
They found that after deprotonation of a 1,1-organodiboronate, it could undergo a nucleophilic 
addition to a carbonyl compound, specifically a ketone, followed by elimination to give the 
corresponding vinyl boronate ester (3-14).16  
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Scheme 3-14. General reaction boron-Wittig reaction scheme proposed by Endo et al.16 
 
In their paper, Endo et al. showed that with a variety of 1,1-organodipinacolboronates 
they generally received both high yields (34-98%) and high stereoselectivity ( >99:1) in favor of 
the E isomer (Table 3-4).  




The reaction was also tested on a variety of a ketones with differing substituents and 
steric bulkiness. Once again, they received high yields with high E-stereoselectivity. They were 
able to show that aryl ketones bearing an electron-withdrawing or electron-donating substituent 
did not change the overall stereoselectivity while only slightly changing the yield of the 
reactions. For example, entry 11 containing an electron-donating methoxy group was obtained in 
74% and 99:1 E:Z whereas entry 10 possesses no electron-withdrawing group on its benzene and 
was obtained in 98% and 99:1 E:Z (Table 3-5).16 
Table 3-5. Variety of ketones and their corresponding yields and selectivity.16 
 
Dr. James Morken took this reaction one step further to control the stereoselectivity of 
synthesized trisubstituted alkenes. For this, they first synthesized the stable alkylborates from 
diboranes. Then, these reactants were used in a boron-Wittig reaction with aldehydes using 
54 
 
LiTMP as base. The first experiment reported was a reaction of hexanal with several bis-
boronate esters 3-20 through 3-22 (Scheme 3-15).17 
Scheme 3-15. Stereospecific synthesis of trisubstituted vinyl boronates proposed by Morken et 
al.17 
 
What Morken et al. noticed was that the stereochemistry was dramatically affected by the 
nature of the boronic ester employed in the form of a geminal bis(boronate). They could 
completely reverse the stereoselectivity based on the specific boronic ester they chose.17 
Specifically, when using a pinacol boronic ester, they received an 88:12 Z:E ratio whereas the 
dimethylpentanediolato (dmpd) boronic ester produced a 27:73 Z:E ratio of products. In order to 
investigate this influence further, they constructed and employed a variety of alpha-branched 
aldehydes and examined their reaction with geminal pinacol-, npg, and dmpd bis(boronates). In 
all cases LiHMDS was used as base, the reactions were conducted by deprotonating the 
bis(boronate) with 1.2 equivalents of LiHMDS at 0 ℃ for 5 minutes, then cooling the reaction 
mixture to -78 ℃, adding the aldehyde, and stirring for four hours (Scheme 3-16).17  
55 
 
Scheme 3-16. Variety of substrates shown by Morken at al. demonstrating substrate selectivity 
based on boronic ester.17 
 
 
Through their data collection, they noticed that usually the E conformation is favored by 
the dimethylpentanediolato (dmpd) boronic ester whereas the Z conformation was favored by the 
pinacol (pin) boronic ester. However, Morken et also remarked that: “the E isomer is favored 
when either large boronate substitutuents (R1) or large aldehyde substituents (R2) are employed, 
and this selectivity can be enhanced with the dmpd ligand. In contrast, when both a small 




To apply this work to our own research, we first had to synthesize the bis(boronates) that 
we would be using. To make the ethyl bis(boronate), copper(I) iodide, lithium methoxide, and 
the diboronate of choice (i.e. either B2dmpd2 or B2pin2), were diluted in a flask with DMF. Then, 
1,1-dibromoethane was added to the flask and it was allowed to stir overnight. In this way, after 
chromatography on silica, boronates 3-27 and 3-28 could be obtained in 43% yield (Scheme 3-
17).  
Scheme 3-17. Synthesis of ethyl bis(boronate)s 3-27 and 3-28. 
 
When Morken’s conditions, -78 ℃ for four hours, were employed with the reaction of 
the bis(pinacol)boronate 3-27,  however, only starting material was recovered. Since we 
understood the enhanced stability of the lactol, we decided that the reaction mixture had to be 
warmed to room temperature in order for the reaction to occur. 
 It was clear from the crude NMR that both the Z and the E isomer were present in 
differing amounts. Post purification, the isomers were separated, isolated, and studied by using 
1- and 2-D NMR techniques. Ultimately it was determined that the reaction gave a 2:5 ratio of 
geometric isomers in favor of the undesired Z-isomer as outlined below.  
After separation of the isomers by chromatography on silica, we set out to determine 
which spectra belonged to which isomer. In this analysis we used three NMR techniques in order 
to spectroscopically differentiate the cis versus trans isomers and confirm their identities. The 
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first step in this process was taking a clean 1H NMR spectra, then utilizing this spectrum for two 
2D NMR techniques, COSY and NOESY, or homonuclear correlation spectroscopy and nuclear 
Overhauser effect spectroscopy respectively. What these three spectra allowed us to do was to 
assign the important alkene and methyl protons and see their correlation to each other as well as 
their relationship within space. In the end, we were looking for a direct spatial relationship 
between a specific hydrogen and hydrogens on a particular methyl group, which was observed 
using the NOESY spectra as illustrated in Figure 3-4 below. 
 
 





The proton assignments for compound 3-19 were designated from spectral work with the 
1H, and 1H NOESY, which allowed us to then look at the spatial relationships, or the closeness in 
space, of these protons. Illustrated by Figure 3-4, there is a clear spatial relationship between the 
proton and methyl group shown. This interaction, shown in the NOE spectra, shows that these 
groups are close in proximity that can only be achieved with an E alkene formation. 
 
 
Figure 3-5. Demonstration of no NOE spatial relationship between proton and methyl group on 
the (Z)-alkene. 
 From Figure 3-5, it can be seen that there is no spatial relationship for compound 3-29 
between the proton and the methyl group indicated. Instead, for this molecule the spatial 
interaction would be with the boronic ester and thus there is no NOESY peak between the methyl 
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and the protons of interest. Thus, from this spectra it was determined that this, the major product 
obtained, represented the Z alkene isomer. 
Although this first attempt gave primarily the undesired isomer, it still provided proof of 
concept that borylation of the lactol was successful. Based on Morken’s work, we assumed that 
switching to the dmpd ester would give the desired E stereochemistry as the major isomer. Using 
the same method used to make the bispinacol(boronate), the bisdmpd(boronate) was synthesized 
and reacted with the lactol (Scheme 3-18). Gratifyingly, there was a single isomer observed from 
the crude and purified NMR spectra. Unfortunately however, through analysis with the same 
NMR techniques described above, it was determined that this reaction was stereoselectively 
producing the Z alkene, rather than the desired E alkene.  
Scheme 3-18. Boron-Wittig reaction forming the undesired E isomer with the lactol. 
 
That we were obtaining the same major product from both the pinacol-diboronate and dmpd-
diboronate was surprising given that Morken generally observed a reversal of selectivity between 
these two types of reagents.17 We noted, however, that our reactions were performed at higher 
temperature (room temp.) compared to Morken (-78 °C) due to the lower reactivity of the lactol. 
This hypothesis was tested by performing the boron-wittig on the aldehyde that was obtained 
from the original synthesis, 2-90 (Scheme 3-19). However, the same results as the lactol were 




Scheme 3-19. Boron-Wittig reaction forming the undesired E isomer with the aldehyde. 
 
We hypothesized that the E-product is favored for our system due to steric considerations 
at the transition state for the elimination step. After addition of the lithiated diboron to the 
aldehyde, the resulting alkoxide must rotate to become syn-coplanar with one of the boron 
groups in order for elimination to occur. As shown in Scheme 3-20, rotation in one direction 
would place the R1 group eclipsed with the boronic ester, whereas the other direction would have 
this group eclipsed with a methyl and a hydrogen eclipsed with the boronic ester. If the boronic 











Scheme 3-20. Fischer projections displaying the steric clash of the Boron-Wittig reaction for the 
formation of both the Z and E isomers. 
 
Due to the incorrect stereoselectivity from the boron Wittig chemistry, it was decided that 
the overall yield of the desired product would be highest if the original synthesis path via the 
vinyl iodide was taken that could then be converted to a vinyl boronate (Scheme 3-21). 
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Scheme 3-21. Proposed retrosynthesis of Reker et al.’s fragment 1. 
 
 Aside from an “eastern” vinyl boronate, vinyl iodide 3-32 also needed to be synthesized 
in order to make the hypothetical COX inhibitor proposed by Reker. An important part of this 
was creating the stereocenter for the hydroxyl on 3-32. For this, we devised two different 
syntheses that could select for either enantiomer (Scheme 3-22). 
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Scheme 3-22. Synthesis of vinyl iodide 3-31.  
 
 The synthesis of 3-32 began with addition of lithiated TMS-acetylene to 
isobutyraldehyde that gave racemic alcohol 3-33 in an 86% yield. The racemic alcohol could 
then be oxidized to the ketone using Jones conditions (89% yield) and then enantioselectively 
reduced with the Noyori catalyst in order to create the S-hydroxyl 3-35 (100% yield, 98% e.e.) or 
stereoselectively acetylated using Novozyme 435 (Table 3-6). This (S)-alcohol was then 
stereoselectively reduced to form the trans alkene using Red-Al in diethyl ether and then 
protected using triethylsilane (TES) to afford 3-37 in 70% yield for the two steps. The TMS 
group was then exchanged with an iodide utilizing an iododesylation using N-iodosuccinimide, 
2,6-lutidine, and 1,1,1,3,3,3,-hexafluoro-2-isopropanol, HFIP in a 52% yield to create the 
coupling fragment 3-32. 
 We also investigated the resolution of racemic alcohol 3-33 as an alternative method for 
the preparation of enantioenriched vinyl iodide 3-32 which can be seen in Table 3-6. As 
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expected, at low conversions the acylated product was obtained in high ee however the recovered 
alcohol was less enantioenriched. Ultimately good yields and enantiomeric excess (ee) could be 
obtained for both compounds by using 200% w/w Novozyme 435 for 65 hr or 100% w/w after 
extended reaction times (113 hr). 
 
Table 3-6. Resolution data for alcohol 3-35. 





(Acetate) e.e. Conversiona 
(S)-Noyori 98% n/a n/a 
Novozyme 5 hr. 6% 97% 14.50% 
Novozyme 23 hr. 26% 98% 22.50% 
Novozyme 65 hr. 51% 96% 39.40% 
Novozyme 65 hr., 
200% w/w enzyme 87% 92% 49.50% 
Novozyme 113 hr. 82% 97% 48.50% 
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 Once both fragments of the target molecule were in hand, Suzuki couplings were 
attempted. The first vinyl boronate taken through the coupling was 3-19 which did not have the 
secondary hydroxyl protected because it was produced through the revised synthetic pathway via 
a lactol boron-Wittig. The first conditions used were taken from Menche et al. as previously 
described consisting of Ba(OH)2, Pd(dppf)Cl2 in DMF at 55 °C for 6 hours.
13 While these initial 
couplings were able to produce some of the desired product, the yields were lower than the 
original Stille coupling, roughly around 40% (Scheme 3-23). 
Scheme 3-23. Initial Suzuki coupling reaction. 
 
 Strangely, the fully protected vinyl boronate (3-4), synthesized through the original 
pathway, failed to undergo successful coupling under the same conditions as the unprotected 3-
19. Instead, the crude NMR spectra showed a mixture of the starting vinyl iodide and vinyl 
boronate, along with another set of peaks that were unidentified. Believing that the Suzuki 
coupling should work, and after checking that both the starting materials were not contaminated 
with impurities, different parameters were investigated that might lead to more consistent results. 
First, the barium hydroxide was activated by heating the solid to 150 ℃ under vacuum for 1.5 
hours, but this led to the formation of more of the unexpected side product. We thought that the 
66 
 
harsher conditions of the more activated base were causing an increase in the side product, so we 
decided to change the base to cesium carbonate, Cs2CO3. Using the same conditions as the 
original Suzuki coupling procedure, some of the product as well as the side product was 
observed in the crude NMR. Thinking that this base could be activating enough for both the 
palladium as well as the pinacol boronate without the extra influence from heating, the reaction 
was allowed stir at room temperature overnight instead of at 55 ℃ for 6 hours. This method was 
successful in minimizing the side product, but starting materials were still present. In a 
subsequent experiment, after the initial overnight reaction, the solution was resubjected with 
another 10 mol % of the palladium catalyst. Under these conditions, yields have been 
consistently around 80% from a method consisting of reacting the starting materials with 10 
mol% Pd(dppf)Cl2 and Cs2CO3 in degassed DMF, letting the solution stir overnight and then 
adding an additional 10 mol% Pd(dppf)Cl2. The solution is then quenched after 6 more hours and 
purified by chromatography on silica (Scheme 3-24). 




 Once the Suzuki coupling had been achieved and optimized, 3-39 and the ZEE coupled 
product, 3-40, were deprotected using 60% HF•pyr, pyridine in THF for 3 days to afford the 
corresponding deprotected products 3-41 and 3-42 in 65% yields (Scheme 3-25).  
Scheme 3-25. The deprotection of 3-39 and 3-40 to 3-41 and 3-42 respectively. 
 
 With the deprotected compounds in hand, they were subjected to both a COX inhibition 
assay as well as an Arabidopsis-based V-ATPase assay. Within the COX assay, neither 
compound was inhibitory up to 125 μM. This could be because neither possess a carboxylic acid, 
which is present on both Reker’s proposed inhibitor as well as the native COX substrate, 
arachidonic acid (Figure 3-6). This carboxylic acid could be a crucial pharmacophore and 





Figure 3-6. Comparison of structures for the COX assay, our synthesized compound, Reker’s 
proposed COX-inhibitor, and the native COX substrate, arachidonic acid. 
 
 The Arabidopsis-based V-ATPase assay gave interesting data. Triene 3-40 containing the 
Z,Z,E-triene found in the natural product showed inhibition as the concentrations were increased 
up to 200 μM. However, the non-natural Z,E,E-triene compound 3-41 did not show any 
inhibition even up to 200 μM. This provides support for the importance of not only the C7 and 
C15 hydroxyls but also the configuration of the conjugated triene connecting these two 




Figure 3-7. Arabidopsis-based V-ATPase assay data showing the inhibited growth of the 








































Chapter 4: Future Work 
 In conclusion, within in this work we were able to test an alternative route to the eastern 
fragment of the archazolids and understand the overall reactivity of a boron-Wittig alternative. 
We were able to nearly synthesize a hypothetical COX and V-ATPase inhibitor. Through this 
synthesis we were able to employ a greener alternative to the Stille cross coupling by using an 
organoborane and a Suzuki coupling. We were also able to show V-ATPase inhibition with the 
truncated fragment of the dihydroarchazolid B as well as demonstrate the importance of the ZZE 
(natural product triene) isomer. Our compounddid not inhibit COX up to 125 μM in our assay, 
suggesting that the carboxylic acid terminus in Reker’s proposed COX inhibitor may be crucial 
for COX inhibitory activity (Figure 3-6).  
 In the future, the V-ATPase inhibition will be tested at higher concentrations for 3-40 as 
well with the (R)-hydroxyl from the western fragment rather than the natural product (S)-
hydroxyl. Compound 3-40 may also be oxidized up to the carboxylic acid for the COX inhibition 
assay using the proposed synthesis shown in Scheme 4-1.  









To a solution of alcohol 2-66 (500 mg, 1.2 mmol) in DCM (1.6 mL), phosphate 3-13 (249 mg, 
1.2 mmol) was added and the solution was cooled to 0℃. DCC (293 mg, 1.42 mmol) was added 
and the solution was allowed to warm to room temperature and stir for 24 hrs. The resulting 
solution was filtered, quenched with H2O (10 mL), extracted with DCM (2 x 10 mL). The 
combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. 
Purification by flash column chromatography on silica (4:1 to 1:1 to 1:2 hexanes:ethyl acetate) 
afforded the ester 3-7 (604 mg, 82%) as an oil. 
IR (ATR) 2931, 2856, 1730, 1612, 1586, 1513, 1460, 1386, 1301, 1246, 1172, 1093, 1023, 962, 
904, 834, 818, 774, 734, 661. 1H NMR (500 MHz, CDCl3): δ 7.24 (d, J = 8.7 Hz, 2H), 6.86 (d, J 
= 8.7 Hz, 2H), 5.59 (ddd, J = 18.6, 9.7, 6.7 Hz, 1H) 5.09 (d, J = 9.7 Hz, 1H), 4.43 (d, J = 10.22 
Hz, 1H) 4.40 (d, J = 10.22 Hz, 1H) 4.11 (m, 4H), 3.80 (s, 3H), 3.59 (t, J = 5.9 Hz, 2H) 3.42 (dd, 
J = 9.25, 5.79 Hz, 1H) 3.35 (dd, J = 9.33, 6.13 Hz, 1H) 3.30 (dd, J = 9.25, 6.31 Hz, 1H) 3.31 (dd, 
J = 9.33, 6.13 Hz, 1H) 2.95 (dq, J = 23.3, 7.4 Hz, 1H), 2.17 (s, 9H), 2.11 (m, 1H), 2.02 (m, 2H), 
1.72 (s, 3H), 1.45 (m, 3H), 1.40 (ddd, J = 18.05, 7.26, 3.40 Hz, 3H), 1.30 (m, 6H), 0.93 (dd, 
6.96, 4.39 Hz, 2H), 0.88 (s, 9H), 0.03 (s, 6H). 13C NMR (125 MHz, CDCl3): δ 159.10, 142.25, 
130.62, 129.16, 120.37, 113.72, 113.70, 73.74, 72.73, 71.73, 62.96, 62.50, 55.28, 40.03, 39.50, 




To a solution of 3-7 (250 mg, 0.398 mmol) in a DCM:H2O mixture (20 mL:0.2 mL), DDQ (180 
mg, 0.795 mmol) was added portion wise and stirred at room temperature for 1 hr. The resulting 
solution was quenched with aqueous sodium bicarbonate (50 mL) and extracted with DCM (2 x 
50 mL). The combined organic extracts were dried over MgSO4, filtered and concentrated in 
vacuo. Purification by flash column chromatography on silica (1:2 to 0:1 hexanes:ethyl acetate) 
afforded the free alcohol (168 mg, 83%) as an oil. 
IR (ATR) 3406, 2928, 2856, 1471, 1455, 1384, 1360, 1253, 1100, 1081, 1030, 1002, 977, 935, 
834, 773, 737, 661. 1H NMR (500 MHz, CDCl3): δ 5.41 (dt, J = 19.99, 9.22 Hz, 1H) 5.09 (dd, 
23.05, 9.70 Hz, 1H), 4.13 (m, 4H), 3.75 (dd, J = 11.58, 3.48 Hz, 0.5H), 3.63 (dd, J = 11.42, 3.81 
Hz, 0.5H), 3.58 (t, J = 6.08 Hz, 2H), 3.49 (ddd, J = 11.46, 6.35, 4.53, 1H), 3.00 (dq, J = 23.93, 
7.01 Hz, 1H), 2.01 (t, J = 7.40, 2H), 1.84 (tt, J = 17.31, 7.10, 5.32, 1H), 1.72 (dd, J = 7.054, 1.36, 
3H), 1.70, (dt, J = 21.94, 1.39, 1.39 Hz, 1H), 1.44 (m, 5H), 1.39 (d, J = 7.27, 1H), 1.36 (d, J = 
7.25, 1H), 1.31 (t, J = 7.06, 7.04, 3.23, 6H), 0.87 (s, 9H), 0.02 (s, 6H) 13C NMR (125 MHz, 
CDCl3): δ 169.28, 141.90, 122.26, 75.58, 75.11, 64.24, 62.94, 40.26, 39.35, 32.28, 25.95, 23.85, 





To a solution of the free alcohol (624 mg, 1.23 mmol) in DCM (6.13 mL), NaHCO3 (515 mg, 
6.13 mmol) was added and stirred 0℃. DMP (520 mg, 1.23 mmol) was added portionwise and 
allowed to stir for 1 hr. The resulting solution was diluted with DCM (20 mL) and stirred 
vigorously with sodium thiosulfate pentahydrate (50 mL) for 30 min. The layers were allowed to 
separate and the organics extracted with DCM (2 x 50 mL). The combined organic extracts were 
dried over MgSO4, filtered and concentrated in vacuo. Purification by flash column 
chromatography on silica (4:1 to 1:1 to 1:2 to 0:1 hexanes:ethyl acetate) afforded the aldehyde 3-
8 (371 mg, 60%) as an oil.  
IR (ATR) 2930, 2857, 1730, 1460, 1387, 1302, 1249, 1171, 1095, 1020, 958, 906, 834, 774, 731, 
660. 1H NMR (500 MHz, CDCl3): δ 9.69 (dd, J = 18.55, 2.35 Hz, 1H), 5.75 (ddd, J = 11.63, 
9.50, 7.75 Hz, 1H), 5.11 (d, J = 9.52, 1H), 4.11 (m, 4H), 3.58 (t, J = 6.01 Hz, 2H), 2.97 (dq, J = 
23.56, 7.31 Hz, 1H), 2.65 (m, 1H), 2.02 (t, J = 6.37 Hz, 2H), 1.76 (d, J = 1.4 Hz, 3H), 1.45 (m, 
5H), 1.40 (dd, J = 7.20, 1.87 Hz, 2H) 1.31 (tt, J = 6.94, 5.41 Hz, 6H), 1.06 (dd, J = 7.16, 2.48 Hz, 





Ba(OH)2•8H2O (340 mg, 1.1 mmol) was heated at 120°C for 1.5 hours under vacuum, then 
allowed to cool to room temperature. THF (7 mL) was added to the flask and allowed to stir fir 
10 minutes. Aldehyde 3-8 (181 mg, 0.36 mmol) was added to the solution and allowed to stir 
overnight. The solution was quenched with aqueous NaHCO3 (20 mL) and extracted with MTBE 
(2 x 20mL). The combined organic extracts were dried over MgSO4, filtered and concentrated in 
vacuo. Purification by flash column chromatography on silica (20:1 to 10:1 to 4:1 hexanes:ethyl 
acetate) afforded the lactone 3-14 (72.2 mg, 57%) as an oil. 
IR (ATR) 2952, 2928, 2856, 1716, 1460, 1359, 1253, 1226, 1199, 1154, 1134, 1099, 1005, 981, 
834, 810, 773, 731, 661. 1H NMR (500 MHz, CDCl3): δ 6.34 (s, 1H), 5.22 (d, J = 9.02 Hz, 1H), 
4.68 (dd, J = 10.50, 9.02 Hz, 1H), 3.57 (m, 2H), 2.45 (ddtt, J = 14.56, 7.17, 4.76, 2.39 Hz, 1H), 
2.03 (t, J = 5.41 Hz, 2H), 1.87 (dd, J = 2.40, 1.54 Hz, 3H), 1.67 (d, J = 1.49 Hz, 3H), 1.46 (m, 
3H), 0.98 (d, J = 7.27 Hz, 3H), 0.85 (d, J = 5.95 Hz, 1H), 0.85 (s, 9H), 0.00 (s, 6H). 13C NMR 
(125 MHz, CDCl3): δ 165.96, 145.52, 143.82, 127.37, 121.50, 80.36, 62.86, 39.24, 34.59, 32.30, 






To a solution of DCM (5 mL) at -78°C, DiBAl-H (0.106 mL, 0.597 mmol) was added and stirred 
for 10 min. Lactone 3-14 (175 mg, 0.498 mmol) was added slowly and allowed to stir for 1 hour. 
The reaction was quenched by stirring vigorously with Rochelle’s salt (20 mL) for 1 hr. The 
organic layers were extracted with DCM (2 x 20 mL), collected, dried over MgSO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography on silica (4:1 hexanes:ethyl 
acetate) afforded the lactol 3-16 (141.4 mg, 80%) as an oil. 
IR (ATR) 3397, 2928, 2856, 1460, 1384, 1253, 110, 1080, 1030, 1002, 976, 935, 833, 773, 737, 
661. 1H NMR (500 MHz, CDCl3): δ 5.48 (s, 1H), 5.16 (m, 2H), 4.24 (t, J = 9.33 Hz, 1H), 3.61 (t, 
J = 5.99 Hz, 3H), 2.89 (s, 1H), 2.09 (m, 1H), 2.06 (m, 2H), 1.73 (m, 3H), 1.71 (d, J = 1.47 Hz, 
3H), 1.50 (m, 3H), 0.89 (s, 9H), 0.86 (d, J = 7.13, 3H), 0.04 (s, 6H). 13C NMR (125 MHz, 
CDCl3): δ 141.98, 132.03, 129.75, 12.65, 91.94, 69.63, 63.01, 39.38, 35.14, 32.41, 25.97, 23.96, 
18.93, 18.35, 16.95, 16.38, -5.27. 
 
To a solution of Tetramethylpiperidine (137 mg, 0.97 mmol) in THF (0.5 mL) at -78°C, n-BuLi 
(0.388 mL, 2.5 M) was slowly added. The solution was allowed to warm to 0°C and 1,1-
dipinacolboroethane (187 mg, 0.65 mmol) was added and stirred. After 10 minutes, lactol 3-16 
(114.6 mg, 0.32 mmol) was added and the solution was allowed to slowly warm to room 
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temperature overnight. The solution was diluted with diethyl ether (10 mL) and filtered through a 
silica plug. The solution was concentrated in vacuo. Purification by flash column 
chromatography on silica (20:1 to 10:1 to 4:1 hexanes:ethyl acetate) afforded the vinyl boronate 
3-19 (22.5 mg, 14%) as an oil. 
IR (ATR) 2977, 2933, 2879, 1460, 1305, 1268, 1215, 1142, 1105, 1016, 967, 846, 775, 736, 669. 
1H NMR (500 MHz, CDCl3): δ 6.68 (s, 1H), 5.13 (d, 9.24 Hz, 1H) 5.07 (d, J = 9.24 Hz, 1H), 
4.01 (t, J = 8.46 Hz, 1H), 3.60 (m, 2H), 2.50 (m, 1H), 2.04 (d, J = 5.90 Hz, 2H), 1.88 (dd, J = 
5.34, 1.34 Hz, 4H) 1.66 (s, 3H), 1.48 (m, 1H) 1.24 (d, J = 3.31 Hz, 3H), 1.21 (d, 4.15 Hz, 12H), 
1.04 (d, J = 7.31 Hz, 2H), 0.89 (s, 9H), 0.84 (d, J = 6.73 Hz, 2H), 0.72 (q, J = 7.29 Hz, 1H) 0.04 
(s, 6H). 13C NMR (125 MHz, CDCl3): δ 140.12, 139.32, 136.49, 130.68, 126.10, 82.85, 72.41, 
63.01, 40.19, 39.50, 32.45, 25.94, 24.81, 24.51, 24.08, 23.94, 23.23, 18.31, 16.80, 9.03, -5.30. 
 
To a solution of DMF (0.6 mL), vinyl boronate 3-19 (100 mg, 0.2 mmol) and vinyl iodide 3-32 
(69 mg, 0.20 mmol) were added. The solution was allowed bubbled with N2 for 10 minutes, then 
Pd(dppf)Cl2 and Ba(OH2)•8H2O were added simultaneously. The solution heated to 55℃ and 
stirred for 6hrs. The reaction was diluted with MTBE (10mL) and quenched with H2O (25 mL). 
The organic layer was dried with MgSO4 and concentrated in vacuo. Purification by flash 
column chromatography on silica (10:1 to 4:1 hexanes:ethyl acetate) afforded the protected 
cis/cis/trans triene 3-38 (30.7 mg, 26%) as an oil. 
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IR (ATR) 2955, 2930, 2875, 1460, 1352, 1344, 1254, 1143, 1103, 1004, 969, 835, 774, 741, 724, 
666. 1H NMR (500 MHz, CDCl3): δ 6.37 (d, J = 15.73 Hz, 1H), 5.84 (s, 1H), 5.64 (dd, J = 15.72, 
7.94 Hz, 1H), 5.16 (d, 9.76 Hz, 1H), 5.10 (d, J = 8.77 Hz, 1H), 4.02 (t, J = 8.77 Hz, 1H), 3.82 (t, 
J = 6.95 Hz, 1H), 3.60 (t, J = 5.89 Hz, 2H), 2.34 (m, 1H), 2.02 (m, 2H), 1.86 (s, 3H), 1.84 (s, 3H) 
1.66 (s, 3H), 1.55 (s, 1H), 1.47 (m, 4H), 1.24 (d, J = 3.80 Hz, 6H), 0.93 (t, J = 7.94 Hz, 9H), 0.89 
(s, 9H), 0.84 (t, J = 6.45 Hz, 3H), 0.56 (q, J = 7.94 Hz, 6H) 0.04 (s, 6H). 13C NMR (125 MHz, 
CDCl3): δ 139.78, 135.13, 132.43, 130.94, 129.00, 128.70, 125.73, 82.91, 72.26, 63.03, 40.50, 
39.49, 35.07, 32.45, 25.97, 24.84, 24.55, 20.35, 18.40, 16.73, 16.36, 9.07, 6.88, 5.04, -5.27. 
 
Cis/cis/trans triene 3-38 (77.2 mg, 0.053 mmol) was added to a solution of THF (1.2 mL) and 
pyridine (0.3 mL). The solution was cooled to 4℃ for 30 min, then a solution of 60% HF•pyr 
(0.2 mL) was added. The reaction mixture was placed in the fridge (4℃) overnight, then it was 
quenched with aqueous NaHCO3 (20 mL) and extracted with ethyl acetate (2 x 10 mL). The 
organic layer was dried with MgSO4 and concentrated in vacuo. Purification by flash column 
chromatography on silica (1:1 to 1:2 hexanes:ethyl acetate) afforded the deprotected cis/cis/trans 
triene 3-41 (30.1 mg, 65%) as an oil. 
IR (ATR) 3338, 2957, 2929, 2870, 1667, 1638, 1585, 1447, 1378, 1366, 1328, 1257, 1203, 1175, 
1136, 1106, 1065, 1003, 973, 935, 858, 817, 769, 736, 697, 667. 1H NMR (500 MHz, C6D6): δ 
6.84 (d, J = 15.85, 1H), 5.78 (dd, J = 15.85, 6.64 Hz, 1H), 5.73 (s, 1H), 5.25 (m, 2H), 4.12 (t, J = 
8.00 Hz, 1H), 3.90 (t, J = 6.22 Hz, 1H), 3.40 (m, 2H), 2.60 (m, 1H), 1.89 (m, 2H), 1.81 (s, 3H), 
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1.78 (s, 3H), 1.57 (s, 3H), 1.36 (m, 5H), 1.03 (d, J = 6.22 Hz, 3H) 0.95 (dd, J = 11.55, 7.11 Hz, 
6H). 13C NMR (125 MHz, C6D6): δ 138.50, 133.57, 132.78, 131.96, 130.53, 129.07, 77.71, 
72.53, 62.10, 40.43, 39.07, 34.12, 32.07, 24.43, 23.70, 19.88, 18.49, 18.06, 16.76, 16.43 
 
 
To a solution of Tetramethylpiperidine (89 mg, 0.63 mmol) in THF (0.4 mL) at -78°C, n-BuLi 
(0.25 mL, 2.5 M) was slowly added. The solution was allowed to warm to 0°C and 1,1-
dipinacolboroethane (89 mg, 0.65 mmol) was added and stirred. After 10 minutes, lactol 3-16 
(111.7 mg, 0.32 mmol) was added and the solution was allowed to slowly warm to room 
temperature overnight. The solution was diluted with diethyl ether (10 mL) and filtered through a 
silica plug. The solution was concentrated in vacuo. Purification by flash column 
chromatography on silica (20:1 to 10:1 to 4:1 hexanes:ethyl acetate) afforded the vinyl boronate 
3-29 (67.5 mg, 43%) as an oil. 
IR (ATR) 2977, 2933, 2879, 1460, 1305, 1268, 1215, 1142, 1105, 1016, 967, 846, 775, 736, 669. 
1H NMR (500 MHz, CDCl3): δ 6.74 (s, 1H), 5.13 (m, 2H), 4.04 (dd, J = 8.91, 7.49 Hz, 1H), 3.61 
(t, J = 5.92 Hz, 2H), 2.34 (m, 1H), 2.03 (m, 2H), 1.84 (s, 3H), 1.71 (s, 3H), 1.65 (s, 3H) 1.48 (m, 
4H), 1.29 (s, 12H), 1.22 (d, J = 3.76 Hz, 3H), 0.89 (s, 9H), 0.04 (s, 6H). 13C NMR (125 MHz, 
CDCl3): δ 142.48, 139.72, 136.49, 130.34, 125.70, 83.08, 72.19, 63.06, 39.53, 32.50, 29.71, 





To a solution of DMF (1.67 mL), Z-vinyl boronate 3-29 (82.3 mg, 0.167 mmol) and vinyl iodide 
3-32 (68.3 mg, 0.20 mmol) were added. The solution was allowed bubbled with N2 for 10 
minutes, then Pd(dppf)Cl2 and Ba(OH2)•8H2O were added simultaneously. The solution heated 
to 55℃ and stirred for 6hrs. The reaction was diluted with MTBE (10mL) and quenched with 
H2O (25 mL). The organic layer was dried with MgSO4 and concentrated in vacuo. Purification 
by flash column chromatography on silica (10:1 to 4:1 hexanes:ethyl acetate) afforded the 
protected cis/cis/trans triene 3-40 (30.7 mg, 26%) as an oil. 
IR (ATR) 2955, 2930, 2875, 1460, 1352, 1344, 1254, 1143, 1103, 1004, 969, 835, 774, 741, 724, 
666. 1H NMR (500 MHz, C6D6): δ 6.33 (d, J = 15.75 Hz, 1H), 6.13 (s, 1H), 5.75 (dd, J = 15.57, 
7.20 Hz, 1H), 5.25 (m, 2H), 4.10 (t, J = 7.79 Hz, 1H), 3.95 (t, J = 6.52 Hz, 1H), 3.54 (t, J = 6.18 
Hz, 2H), 2.53 (dtt, J = 10.06, 6.83, 6.78 Hz, 1H), 1.95 (m, 2H), 1.82 (s, 3H), 1.79 (s, 3H) 1.57 (s, 
3H), 1.48 (m, 5H), 1.04 (t, J = 7.90 Hz, 9H), 0.99 (s, 9H), 0.95 (dd, J = 6.89, 1.60 Hz, 3H) 0.88 
(t, J = 6.89 Hz, 6H), 0.66 (dq, J = 8.19, 2.15 Hz, 6H), 0.07 (s, 6H). 13C NMR (125 MHz, C6D6): 
δ 138.01, 135.32, 134.38, 134.20, 131.90, 130.51, 130.32, 127.03, 78.98, 71.91, 62.74, 40.57, 






Cis/trans/trans triene 3-40 (56 mg, 0.097 mmol) was added to a solution of THF (1.2 mL) and 
pyridine (0.3 mL). The solution was cooled to 4℃ for 30 min, then a solution of 60% HF•pyr 
(0.2 mL) was added. The reaction mixture was placed in the fridge (4℃) overnight, then it was 
quenched with aqueous NaHCO3 (20 mL) and extracted with ethyl acetate (2 x 10 mL). The 
organic layer was dried with MgSO4 and concentrated in vacuo. Purification by flash column 
chromatography on silica (1:1 to 1:2 hexanes:ethyl acetate) afforded the deprotected 
cis/trans/trans triene 3-42 (32.6 mg, 96%) as an oil. 
IR (ATR) IR (ATR) 3338, 2957, 2929, 2870, 1667, 1638, 1585, 1447, 1378, 1366, 1328, 1257, 
1203, 1175, 1136, 1106, 1065, 1003, 973, 935, 858, 817, 769, 736, 697, 667. 1H NMR (500 
MHz, C6D6): δ 6.32 (d, J = 15.70 Hz, 1H), 6.09 (s, 1H), 5.66 (dd, J = 15.65, 6.81 Hz, 1H), 5.26 
(dq, J = 10.08, 1.52 Hz, 2H), 4.13 (dd, J = 8.84, 6.14 Hz, 1H), 3.78 (t, J = 6.98 Hz, 1H), 3.37 (t, 
J = 6.67 Hz, 2H), 2.53 (dq, J = 9.92, 6.74 Hz, 1H), 1.91 (m, 2H), 1.80 (d, J = 12.05, 6H), 1.69 
(sept., J = 6.67 Hz, 1H), 1.56 (s, 3H), 1.36 (m, 4H), 1.03 (d, J = 6.84 Hz, 3H), 0.97 (d, J = 6.67 
Hz, 3H), 0.90 (d, J = 6.84 Hz, 3H). 13C NMR (125 MHz, C6D6): δ 138.02, 135.53, 134.30, 
131.64, 130.85, 130.10, 126.98, 77.60, 72.00, 62.18, 40.54, 39.36, 34.22, 32.24, 24.05, 23.89, 








t-BuLi (0.11 mL, 1.7M) was added to dry diethyl ether (1 mL) at -78℃. Vinyl iodide (50 mg, 
0.082 mmol) was added to the solution and stirred for 10 minutes. Then, isoproproxy borate 
(0.03 mL, 0.123 mmol) was added and the solution was stirred for 30 minutes before pinacol (20 
mg, 0.164 mmol) was added and the solution warmed to room temperature. It was allowed to stir 
overnight before being diluted with MTBE (10 mL), washed with NH4Cl (10 mL), water (10 
mL), and finally brine (10 mL). The organic extracts were dried with MgSO4 and concentrated in 
vacuo. The oil was then resubjected into dry THF (1 mL) and pinacol (20 mg, 0.164 mmol) for 2 
hours. The solution was concentrated in vacuo. Purification by flash column chromatography on 
silica (20:1 to 10:1 hexanes:ethyl acetate) afforded the fully protected vinyl boronate 3-4 (27.3 
mg, 53%) as an oil. 
IR (ATR): 2954, 2928, 2856, 1471, 1461, 1388, 1378, 1370, 1333, 1299, 1253, 1214, 1165, 
1143, 1101, 1057, 1031, 1005, 963, 938, 812, 772, 695, 668. 1H NMR (500 MHz, CDCl3): δ 6.69 
(s, 1H), 5.10 (d, J = 8.83 Hz, 1H), 5.05 (d, J = 8.83 Hz, 1 H) 4.15 (dd, J = 9.16, 5.72 Hz, 1H), 
3.60 (t, J = 6.09 Hz, 2H), 2.64 (m, 1H), 1.98 (t, J = 7.38 Hz, 3H), 1.87 (s, 3H), 1.85 (s, 3H), 1.57 
(d, J = 1.57 Hz, 3H) 1.45 (m, 3H), 1.28 (s, 12H), 0.89 (s, 12H) 0.85 (s, 9H), 0.04 (s, 6H), -0.02 
(d, J = 14.42 Hz, 6H). 13C NMR (125 MHz, CDCl3): δ 138.15, 135.33, 133.45, 132.69, 127.21, 





Vinyl boronate 3-4 (58.8 mg, 0.093 mmol) and vinyl iodide 3-32 (25 mg, 0.076 mmol) was 
dissolved in DMF (1 mL). The solution was degassed by the freeze, pump, and thaw method two 
times. Then, Pd(dppf)Cl2 (4 mg, 0.004 mmol) and Cs2CO3 (40 mg, 0.12 mmol) was added and 
the solution was freeze, pump, thawed once again. The resulting solution was allowed to stir 
overnight and then an additional equivalent of Pd(dppf)Cl2 (4 mg, 0.004 mmol) was added. The 
solution was allowed to stir for an additional 6 hours, then it was diluted with MTBE (5 mL) and 
quenched with water (20 mL). The solution was extracted with MTBE (2x20 mL). The combined 
organic extracts were dried with MgSO4 and concentrated in vacuo. Purification by flash column 
chromatography on silica (20:1 hexanes:ethyl acetate) afforded the fully protected cis/cis/trans 
triene 3-39 (41.9 mg, 80%) as an oil. The product was unable to be purified away from a side 
product and this mixture was taken direction into the next reaction. 
1H NMR (500 MHz, C6D6): δ 6.69 (d, J = 15.70 Hz, 1H) 6.01 (s, 1H), 5.77 (dd, J = 15.70, 7.70 
Hz, 1H) 5.33 (m, 2H), 4.28 (dd, J = 8.86, 5.49 Hz, 1H), 3.98 (t, J = 6.72 Hz, 1H), 3.55 (s, 2H), 
1.96 (m, 2H), 1.94 (s, 3H), 1.87 (s, 3H) 1.79 (m, 1H), 1.59 (s, 3H) 1.50 (m, 4H), 1.13 (d, J = 






Copper (I) iodide (197 mg, 1.04 mmol), lithium methoxide (980 mg, 25.9 mmol), and B2Pin2 (5 
g, 19.7 mmol) were added to a dried flask. The solids were dissolved in DMF (21 mL) and 
allowed to stir for 10 minutes. 1,1-dibromoethane (1.95 g, 10.4 mmol) was added to the flask and 
the solution was allowed to stir overnight. The resulting solution was quenched with water (50 
mL) and extracted with hexanes (2 x 30 mL). The organic extracts were dried with MgSO4 and 
concentrated in vacuo. Purification by flash column chromatography on silica (20:1 
hexanes:ethyl acetate) afforded the bis(pinacol)boronate 3-27 (1.2464 g, 43%) as an oil. The 
spectroscopic data correlated the published data. 
 
 
Copper (I) iodide (39.5 mg, 0.21 mmol), lithium methoxide (197 mg, 5.18 mmol), and B2dmpd2 
(1 g, 3.94 mmol) were added to a dried flask. The solids were dissolved in DMF 4.5 mL) and 
allowed to stir for 10 minutes. 1,1-dibromoethane (389 mg, 2.1 mmol) was added to the flask and 
the solution was allowed to stir overnight. The resulting solution was quenched with water (50 
mL) and extracted with hexanes (2 x 30 mL). The organic extracts were dried with MgSO4 and 
concentrated in vacuo. Purification by flash column chromatography on silica (20:1 
hexanes:ethyl acetate) afforded the bis(dmpd)boronate 3-28 (439.3 mg, 68%) as an oil. The 





n-Butyllithium (7.2 mL, 2.5M) was added dropwise to trimethylsilylacetylene (3.0 mL, 21.6 
mmol) in THF (90 mL) at -78⁰C and stirred for 30 minutes. Isobutyraldehyde (1.65 mL, 18.0 
mmol) was then added and the mixture was stirred for 90 minutes. The crude reaction mixture 
was quenched with aq. NH4Cl (100 mL) and extracted with MTBE (2 x 100 mL). The combined 
organic extracts were dried over MgSO4, filtered through cotton, and concentrated under 
vacuum. The crude product was purified by chromatography over silica gel (10:1 
Hexanes:EtOAc) to give 3-33 (3.16 g, 18.5 mmol, 85.8%) as an oil. 
Rf = 0.55 in 4:1. IR (ATR): 3333, 3130, 3057, 3026, 2960, 2927, 2171, 1601, 1493, 1452, 1384, 
1250, 1030, 992, 839, 758, 696. 1H NMR (500 MHz, CDCl3): δ 4.17 (d, J = 5.8 Hz, 1H) 1.89 (o, 
J = 5.8 Hz, 1H), 1.03 (d, J = 6.8 Hz, 3H), 1.01 (d, J = 6.8 Hz, 3H), 0.20 (s, 9H). 13C NMR (500 
MHz, CDCl3): δ 105.54, 90.19, 68.35, 34.45, 18.04, 17.44, -0.10.  
  
 
Jones’ reagent (CrO3 in aqueous H2SO4) (4.62 mL, 18.5 mmol) was added dropwise to a solution 
of compound 3-33 (3.16 g, 18.5 mmol) in acetone (90 mL) and the mixture was stirred for 20 
minutes. Additonal Jones’ reagent (0.2 mL) was then added dropwise until the reaction mixture 
began to turn yellow. Isopropanol (1 mL) was then added dropwise to the mixture until the 
reaction turned blue to quench the reaction. The crude reaction mixture was extracted with 
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MTBE (2 x 45 mL), dried over MgSO4, filtered through cotton, and concentrated under vacuum 
to give 3-34 (2.78 g, 16.5 mmol, 89.4%) that could be used without further purification. 
 Rf = 0.75 in 4:1. IR (ATR): 2969, 2936, 2903, 2875, 2151, 1742, 1676, 1467, 1385, 1252, 1183, 
1129, 1065, 1004, 962, 891, 842, 761. 1H NMR (500 MHz, CDCl3): δ 2.66 (sept., J = 7.0 Hz, 
1H), 1.21 (d, J = 7.0 Hz, 6H), 0.27 (s, 9H). 13C NMR (500 MHz, CDCl3): δ 191.98, 101.06, 
98.78, 42.84, 17.87, -0.72.  
  
 
Triethylamine (6.72 mL, 50.5 mmol) was added to (S,S)-Noyori-TsDPEN (0.210 g, 0.33 mmol) 
in DCM (55 mL). This mixture was added to compound 3-34 and the solution was then cooled to 
0 ⁰C. Formic acid (4.36 mL, 115.5 mmol) was added dropwise over 100 minutes and the reaction 
was then stirred to room temperature for 15 hours. The crude mixture was concentrated under 
vacuum. Pentane (62 mL), sodium carbonate (9.68 g, 70.0 mmol), and MgSO4 (5.92 g) were 
added and the resulting mixture was stirred for 2 hours before filtering through cotton and 
concentrating under vacuum. The crude product was purified by chromatography over silica gel 
(gradient of 20:1 to 10:1 to 4:1 to 1:1) giving 3-35 (2.8083 g, 16.5 mmol, 100%) as an oil.  
Rf = 0.62 in 4:1. IR (ATR): 3345, 2960, 2900, 2874, 2173, 1728, 1470, 1408, 1383, 1368, 1249, 
1131, 1032, 992, 838, 759, 698. 1H NMR (500 MHz, CDCl3): δ 4.17(d, J = 5.9 Hz, 1H), 1.89(o, 
J = 5.9 Hz, 1H), 1.03(d, J = 6.8 Hz), 1.01(d, J = 6.8 Hz, 2H), 0.20 (s, 9H). 13C NMR (500 MHz, 





Sodium bis(2-methoxyethoxy)aluminum hydride (2.65 mL, 3.07M) was added dropwise to 
compound 3-35 (1.0313 g, 6.05 mmol) in diethyl ether (15 mL) at 0 ⁰C and stirred to room 
temperature for 15 hours. The crude reaction mixture was quenched by stirring with ethyl acetate 
(50 mL) and aq. Rochelle’s salt (50 mL) for 1 hour. The quenched mixture was extracted with 
ethyl acetate (2 × 50 mL). The combined organic fractions were dried over MgSO4, filtered 
through cotton, and concentrated under vacuum. The crude product was purified by 
chromatography over silica gel (gradient of 20:1 to 10:1) giving 3-36 (0.859 g, 4.98 mmol, 
82.4%) as an oil. 
Rf = 0.53 in 4:1. IR (ATR): 3355, 3057, 3025, 2956, 2923, 1721, 1621, 1601, 1582, 1493, 1452, 
1247, 1025, 989, 866, 835, 762, 742, 694. 1H NMR (500 MHz, CDCl3): δ 6.06 (dd, J = 9.5, 5.6 
Hz, 1H), 5.88 (dd, J = 9.4, 1.3 Hz, 1H), 3.88 (s, 1H), 1.76 (o, J = 6.9 Hz, 1H), 0.94 (d, J = 7.1 Hz, 
3H), 0.92 (d, J = 7.2 Hz, 3H), 0.10 (s, 9H). 13C NMR (500 MHz, CDCl3): δ 146.98, 130.48, 79.61, 
33.55, 18.35, 17.64, -1.26.  
  
 
Chlorotriethylsilane (0.117 mL, 0.696 mmol) was added to a solution of compound 3-36 (0.100 
g, 0.580 mmol) and imidazole (0.0790 g, 1.16 mmol) in DCM (1.66 mL) at 0⁰C and then stirred 
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at room temperature for 3 hours. The crude reaction mixture was quenched with water (10 mL) 
and extracted with DCM (2 × 10 mL). The combined organic fractions were dried over MgSO4, 
filtered through cotton, and concentrated under vacuum. The crude product was purified by 
chromatography over silica gel (20:1) to give 3-37 (0.1453 g, 0.501 mmol, 86.3%) as an oil. 
Rf = 0.85 in 20:1. IR (ATR): 2954, 2911, 2876, 1620, 1459, 1414, 1259, 1059, 1004, 992, 872, 
834, 721, 691. 1H NMR (500 MHz, CDCl3): δ 5.97 (dd, J = 18.7, 6.5 Hz, 1H), 5.75 (dd, J = 18.8, 
1.1 Hz, 1H), 3.77 (ddd, J = 6.4, 1.0 Hz, 1H), 1.66 (o, J = 6.5 Hz, 1H), 0.96 (t, J = 8.0 Hz, 9H), 
0.90 (d, J = 6.8, 3H), 0.85 (d, J = 6.8 Hz, 3H), 0.59 (dq, J = 7.7, 2.5 Hz, 6H), 0.08 (s, 9H). 13C 
NMR (500 MHz, CDCl3): δ 147.91, 129.98, 81.17, 34.35, 18.39, 18.18, 6.88, 5.00, -1.32.  
  
 
N-iodosuccinimide (0.169 g, 0.751 mmol) was added to compound 3-37 (0.144 g, 0.501 mmol) 
and 2,6-lutidine (0.081 mL, 0.701 mmol) in 1,1,1,3,3,3-hexafluoroisopropanol (2.00 mL) at 0⁰C 
and stirred for 15 minutes. The crude reaction mixture was quenched with water (5 mL) and 
extracted with DCM (2 × 10 mL). The combined organic fractions were washed in sequence with 
sodium thiosulfate (25 mL), hydrochloric acid (25 mL, 1M), water (25 mL), sodium bicarbonate 
(25 mL), then dried over MgSO4, filtered through cotton, and concentrated under vacuum. The 
crude product was purified by chromatography over silica gel (hexanes) to give 3-32 (0.0885 g, 
0.260 mmol, 52.0%) as an oil. 
Rf = 0.33 in hexanes. IR (ATR): 2955, 2910, 2875, 1607, 1459, 1414, 1384, 1364, 1238, 1182, 
1162, 1118, 1103, 1071, 1004, 948, 828, 723. 1H NMR (500 MHz, CDCl3): δ 6.53 (dd, J = 14.4, 
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6.8 Hz, 1H), 6.20 (dd, J = 14.4, 1.1 Hz, 1H), 3.83 (ddd, J = 6.7, 5.7, 1.1 Hz), 1.69 (do, J = 6.8, 
1.1 Hz, 1H), 0.97 (t, J = 8.0 Hz, 9H), 0.91 (d, J = 6.8, 3H), 0.87 (d, J = 6.8, 3H), 0.60 (q, J = 8.2 
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